Piper Sandler analyst Joseph Catanzaro downgraded Achilles Therapeutics to Neutral from Overweight with a price target of $2, down from $8. The analyst says additional data for the CHIRON and THETIS trials show that while 18 new patients have demonstrated meaningful manufacturing improvements and a step-up in cNeT cell dose, this has not translated to improved clinical activity. The firm continues to see neoantigen-reactivity as a potential next-generation TIL approach, but believes the “progress here continues to be incremental.” A “step-function change is needed” to get to clinical activity where there could be a path forward, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHL:
- Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
- Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
- Achilles Therapeutics Plc (ACHL) Q4 Earnings Cheat Sheet
- Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference